Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Do-It-Yourself Home Style on a Careful spending plan: Imaginative Thoughts and Tasks - 2‘Democratizing space’ is more than just adding new players – it comes with questions around sustainability and sovereignty
- 3Iran, Hezbollah fire rockets at Israel during Passover celebrations
- 4Flourishing in a Cutthroat Work Market: Vocation Methodologies
- 5How to watch 'A Charlie Brown Christmas' for free this weekend
- Weight-loss pill approval set to accelerate food industry product overhauls
- Recalled Super Greens diet supplement powder sickens 45 with salmonella
- Sustaining Public activity and Connections: Key Methodologies
- Manual for Tracking down the Nearby Business sectors and Marketplaces
- The Response to Independence from the rat race: Methodologies for Creating Financial momentum
- Peloton recalls more than 800,000 bikes after broken seat posts injure users
- Space Condos to Lift Your Metropolitan Living
- Conquering Language Boundaries: Individual Accounts of Multilingualism
- Building a Maintainable Closet: Individual Excursions in Moral Style
